Compare DVN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DVN | NTRA |
|---|---|---|
| Founded | 1971 | 2003 |
| Country | United States | United States |
| Employees | N/A | 6140 |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 28.2B |
| IPO Year | 1999 | 2015 |
| Metric | DVN | NTRA |
|---|---|---|
| Price | $49.32 | $188.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 15 |
| Target Price | $50.15 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 13.4M | 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $17,188,000,000.00 | $210,939,000.00 |
| Revenue This Year | $28.91 | $18.08 |
| Revenue Next Year | $8.55 | $19.65 |
| P/E Ratio | $249.03 | ★ N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $30.24 | $131.81 |
| 52 Week High | $52.71 | $256.36 |
| Indicator | DVN | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 41.77 |
| Support Level | $34.53 | $187.27 |
| Resistance Level | $52.33 | $220.74 |
| Average True Range (ATR) | 1.35 | 10.93 |
| MACD | -0.10 | -1.83 |
| Stochastic Oscillator | 67.29 | 10.07 |
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two-thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. If the merger with Coterra is successful, it will have a foothold in the gas-driven Appalachian Basin, as well. At the end of 2025, Devon reported net proved reserves of 2.4 billion barrels of oil equivalent, up from 2.2 billion in 2024. Net production averaged roughly 840,000 barrels of oil equivalent per day in 2025 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.